Evidence map›Paper›PMID 40123148›Full record

ArticleThoracic cancer2025

Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan.

Satoshi Miyamoto, Akihiro Tsukaguchi, Hanako Kuhara, Taiichiro Otsuki, Takayuki Shiroyama, Motohiro Tamiya, Akihiro Tamiya, Kazumi Nishino, Yoshito Takeda, Takashi Kijima and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Satoshi MiyamotoDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.ORCID https://orcid.org/0009-0003-6397-0207
Akihiro TsukaguchiDepartment of Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Osaka, Japan.
Hanako KuharaDepartment of Internal Medicine, Saito Yukoukai Hospital, Ibaraki, Osaka, Japan.
Taiichiro OtsukiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Takayuki ShiroyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Motohiro TamiyaDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Akihiro TamiyaDepartment of Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Osaka, Japan.
Kazumi NishinoDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Yoshito TakedaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Takashi KijimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Meinoshin OkumuraDepartment of Thoracic Surgery, NHO Osaka Toneyama Medical Center, Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masahide MoriDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLenvatinib is recommended for the treatment of advanced and recurrent thymic carcinomas. However, there is a paucity of data on lenvatinib's use in real-world clinical practice. The aim of this study was to evaluate the efficacy and safety of lenvatinib in patients with thymic carcinoma.

methodsThis multicenter retrospective cohort study assessed the efficacy and tolerability of lenvatinib in the treatment of patients with advanced or recurrent thymic carcinoma between March 2021 and March 2024.

resultsTwenty-seven patients from six institutions in Japan were enrolled in this study. The median progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were 9.0 months (95% confidence interval [CI] 4.8-14.5), 33% (95% CI 16.5%-54%), and 85% (95% CI 66.3%-95.8%), respectively. Although the number of patients was small, the median PFS of the first-, second-, and third- or later-line treatment groups was 21.3 months (n = 5), 9.0 months (n = 13), and 5.8 months (n = 9) (p = 0.171), respectively. Dose reduction was required in all patients, with 17 (63%) presenting grade ≥ 3 adverse events, including hypertension in seven patients and proteinuria in six. No grade ≥ 4 adverse events were observed.

conclusionThe real-world efficacy and safety of lenvatinib are consistent with those reported in previous clinical trials of second-line lenvatinib. Furthermore, despite the relatively small sample size, our findings suggest that lenvatinib may be effective for the treatment of thymic carcinoma.

Indexed as

Antineoplastic AgentsNeoplasm Recurrence, LocalPhenylurea CompoundsQuinolinesThymomaThymus NeoplasmsAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolineslenvatinibretrospective studythymic carcinomavascular endothelial growth factor

Identifiers

PMID40123148
PMCPMC11930915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.